Thursday, 15 October 2026European Markets

SOLVAC NOM(RETAIL) And TESSENDERLO Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(VIANEWS) - SOLVAC NOM(RETAIL) (SOLV.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Basic Materials sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SOLVAC NOM(RETAIL) (SOLV.BR) €109.00 4.47% 11.29%
TESSENDERLO (TESB.BR) €24.30 3.07% 8.87%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SOLVAC NOM(RETAIL) (SOLV.BR)

4.47% Forward Dividend Yield and 11.29% Return On Equity

Solvac S.A. operates as an advanced materials and specialty chemicals company in Belgium. It offers specialty polymers, composite materials, soda ash, peroxides, silica, and coatis. The company was incorporated in 1983 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, SOLVAC NOM(RETAIL) has a trailing twelve months EPS of €19.

PE Ratio

SOLVAC NOM(RETAIL) has a trailing twelve months price to earnings ratio of 5.74. Meaning, the purchaser of the share is investing €5.74 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.29%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 57.6%, now sitting on 410.1M for the twelve trailing months.

More news about SOLVAC NOM(RETAIL).

2. TESSENDERLO (TESB.BR)

3.07% Forward Dividend Yield and 8.87% Return On Equity

Tessenderlo Group NV, together with its subsidiaries, engages in the agriculture, valorizing bio-residuals, energy, and industrial solution businesses worldwide. It operates through four segments: Agro, Bio-Valorization, Industrial Solutions, and T-Power. The Agro segment engages in the production, marketing, and trading of crop nutrients, including liquid crop and potassium sulfate fertilizers, as well as crop protection products. This segment offers its specialty fertilizers under the Thio-Sul, KTS, K-Row 23, CaTs, GranuPotasse, and SoluPotasse brands. The Bio-Valorization segment produces, sells, and trades in gelatins and collagen peptides, and proteins and fats for food, pharma, health and nutrition, pet food, agriculture, aqua feed, animal feed, energy, biodiesel, oleo-chemistry, and sanitary markets. The Industrial Solutions segment is involved in the production, sale, and trading of plastic pipe systems; water treatment chemicals; and other industrial activities, such as the production and sale of mining and industrial auxiliaries. The T-Power segment produces electricity through a combined cycle gas turbine of 425 MW capacity. It serves agriculture, food, industry, construction, health, and consumer goods end markets. The company was founded in 1919 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, TESSENDERLO has a trailing twelve months EPS of €2.73.

PE Ratio

TESSENDERLO has a trailing twelve months price to earnings ratio of 8.9. Meaning, the purchaser of the share is investing €8.9 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.87%.

Volume

Today's last reported volume for TESSENDERLO is 11517 which is 59.06% below its average volume of 28136.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TESSENDERLO's stock is considered to be overbought (>=80).

More news about TESSENDERLO.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com